| ²é¿´: 271 | »Ø¸´: 9 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
¸÷λ¸ßÊÖÇë½ø
|
|||
The active substance manufacturer's restricted ("closed" part of the EDMF should follow thestructure of Module 3.2.S of the CTD. A separate Quality Overall Summary for the information included in the active substance manufacturer's restricted ("closed" part shouldalso be provided, as part of the EDMF. ÕâÒ»¶ÎÊDz»ÊÇ˵Ã÷CTDÖÐÖÁÉÙÊÇÅ·ÖÞµÄÖÆ¼ÁÉ걨,³ýÁËÊÚȨÐÅÒÔÍâ,»¹ÊÇÐèÒªÔÁÏÒ©DMFµÄ¹«¿ª²¿·ÖÎļþºÍ·Ç¹«¿ª²¿·ÖÎļþÁ˰¡,²»ÊÇ˵²»Ó÷ǹ«¿ªµÄ²¿·ÖÂð, |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸¹ãÒ½ ҩѧר˶ ×Ü·Ö383 ÒѹýËļ¶ Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çó¹ºÊ±¼ä³¤Ò»Ð©µÄÏõËáîÊ
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ297È˻ظ´
ÇëÎÊÔõô²ÅÄÜÔÚÓÐôÈ»ù´æÔÚµÄÇé¿öÏ£¬Ö»¸ø·ÓôÇ»ùÉϼ׻ù
ÒѾÓÐ6È˻ظ´
²Î±ÈÖÆ¼Á£¬×Ô¼º×öµÄPKÊý¾ÝÓëIF×ÊÁϱ¨µÀµÄÊý¾ÝÏà²îºÜ´ó
ÒѾÓÐ2È˻ظ´
ÆíÇóÖб¾×Ó
ÒѾÓÐ0È˻ظ´
¸÷λ´óÀУ¬H¿ÚÃæÉÏʲôʱºò»áÆÀ£¿£¿£¿
ÒѾÓÐ30È˻ظ´
2026Äêɽ¶«´óѧº£ÑóѧԺÉúÎïÓëÒ½Ò©²©Ê¿ÕÐÉú-Àîϼ¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
²©Ê¿Ñо¿ÉúÕÐÉú
ÒѾÓÐ0È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
zhoudingcheng
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 6594.2
- Ìû×Ó: 334
- ÔÚÏß: 61.7Сʱ
- ³æºÅ: 117382
- ×¢²á: 2005-11-26
- רҵ: Óлú·ÖÎö

5Â¥2007-03-05 12:46:16
2Â¥2007-03-04 19:00:57
3Â¥2007-03-04 19:01:12
4Â¥2007-03-05 09:21:36











part of the EDMF should follow the
»Ø¸´´ËÂ¥
10